The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to offer a greater substantial decrease in body weight and improve metabolic marke